Autolus Therapeutics (AUTL) Short Interest Ratio & Short Volume → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free AUTL Stock Alerts $6.23 -0.01 (-0.16%) (As of 08:00 AM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Autolus Therapeutics Short Interest DataCurrent Short Volume3,150,000 sharesPrevious Short Volume2,770,000 sharesChange Vs. Previous Month+13.72%Dollar Volume Sold Short$18.33 millionShort Interest Ratio / Days to Cover1.9Last Record DateMarch 15, 2024Outstanding Shares232,270,000 sharesPercentage of Shares Shorted1.36%Today's Trading Volume1,680 sharesAverage Trading Volume1,610,655 sharesToday's Volume Vs. Average0% Short Selling Autolus Therapeutics ? Sign up to receive the latest short interest report for Autolus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAUTL Short Interest Over TimeAUTL Days to Cover Over TimeAUTL Percentage of Float Shorted Over Time Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> Autolus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20243,150,000 shares $18.33 million +13.7%N/A1.9 $5.82 2/29/20242,770,000 shares $16.62 million -10.7%N/A1.7 $6.00 2/15/20243,100,000 shares $21.95 million +5.4%N/A1.9 $7.08 1/31/20242,940,000 shares $17.70 million +21.5%N/A2.1 $6.02 1/15/20242,420,000 shares $17.40 million +12.0%N/A2.1 $7.19 12/31/20232,160,000 shares $13.91 million -18.5%N/A2.2 $6.44 Get the Latest News and Ratings for AUTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20232,650,000 shares $13.28 million +26.8%N/A3.2 $5.01 11/30/20232,090,000 shares $8.95 million +41.2%N/A3.3 $4.28 11/15/20231,480,000 shares $6.28 million +0.7%N/A2.8 $4.24 10/31/20231,470,000 shares $4.15 million -2.0%N/A3.7 $2.82 10/15/20231,500,000 shares $3.53 million +5.6%N/A4.2 $2.35 9/30/20231,420,000 shares $3.31 million -11.8%N/A3.8 $2.33 9/15/20231,610,000 shares $4.62 million +17.5%N/A3.6 $2.87 8/31/20231,370,000 shares $4.40 million -16.5%N/A3 $3.21 8/15/20231,640,000 shares $4.51 million -12.3%N/A2.7 $2.75 7/31/20231,870,000 shares $6.04 million +18.4%N/A2.6 $3.23 7/15/20231,580,000 shares $3.89 million +6.0%N/A2.2 $2.46 6/30/20231,490,000 shares $3.55 million +4.9%N/A2.2 $2.38 6/15/20231,420,000 shares $4.02 million -11.8%N/A2.1 $2.83 5/31/20231,610,000 shares $5.01 million +117.7%N/A2.3 $3.11 5/15/2023739,700 shares $1.86 million -14.1%N/A1.3 $2.52 4/30/2023861,000 shares $1.56 million -33.3%N/A1.6 $1.81 4/15/20231,290,000 shares $2.32 million -24.1%N/A2.5 $1.80 3/31/20231,700,000 shares $3.13 million +40.5%N/A3.1 $1.84 3/15/20231,210,000 shares $2.53 million +7.1%N/A2.2 $2.09 2/28/20231,130,000 shares $2.19 million -10.3%N/A1.5 $1.94 2/15/20231,260,000 shares $2.42 million +43.6%N/A1.7 $1.92 1/31/2023877,400 shares $1.89 million +75.3%N/A1.3 $2.15 1/15/2023500,400 shares $1.05 million -24.3%N/A0.9 $2.10 12/30/2022661,000 shares $1.26 million +42.4%N/A1.2 $1.90 12/15/2022464,200 shares $858,770.00 -45.8%N/A1 $1.85 11/30/2022856,700 shares $2.26 million -19.2%N/A4.7 $2.64 11/15/20221,060,000 shares $2.12 million +16.9%N/A6.7 $2.00 10/31/2022906,900 shares $2.58 million -9.3%N/A5.8 $2.85 10/15/20221,000,000 shares $3.25 million -3.9%N/A6.4 $3.25 9/30/20221,040,000 shares $2.23 million -3.7%N/A7.7 $2.14 9/15/20221,080,000 shares $2.98 million -4.4%N/A8.4 $2.76 8/31/20221,130,000 shares $3.73 million -3.4%N/A8.1 $3.30 8/15/20221,170,000 shares $4.40 million -10.7%N/A8 $3.76 7/31/20221,310,000 shares $3.65 million -7.8%N/A7.8 $2.79The Small Biotech with a BIG Cancer Solution (Ad)There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.Get the full story here >>> AUTL Short Interest - Frequently Asked Questions What is Autolus Therapeutics' current short interest? Short interest is the volume of Autolus Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 3,150,000 shares of AUTL short. Learn More on Autolus Therapeutics' current short interest. What is a good short interest ratio for Autolus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AUTL shares currently have a short interest ratio of 2.0. Learn More on Autolus Therapeutics's short interest ratio. Which institutional investors are shorting Autolus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Autolus Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Autolus Therapeutics' short interest increasing or decreasing? Autolus Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,150,000 shares, an increase of 13.7% from the previous total of 2,770,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Autolus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Autolus Therapeutics: ADMA Biologics, Inc. (3.50%), Adaptimmune Therapeutics plc (0.31%), Vir Biotechnology, Inc. (6.17%), Inhibrx, Inc. (4.50%), 4D Molecular Therapeutics, Inc. (17.08%), Scholar Rock Holding Co. (13.54%), Tarsus Pharmaceuticals, Inc. (21.04%), Fusion Pharmaceuticals Inc. (9.35%), BioCryst Pharmaceuticals, Inc. (14.82%), Relay Therapeutics, Inc. (9.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Autolus Therapeutics stock? Short selling AUTL is an investing strategy that aims to generate trading profit from Autolus Therapeutics as its price is falling. AUTL shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Autolus Therapeutics? A short squeeze for Autolus Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AUTL, which in turn drives the price of the stock up even further. How often is Autolus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AUTL, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ADMA Biologics Short Squeeze Adaptimmune Therapeutics Short Squeeze Vir Biotechnology Short Squeeze Inhibrx Short Squeeze 4D Molecular Therapeutics Short Squeeze Scholar Rock Short Squeeze Tarsus Pharmaceuticals Short Squeeze Fusion Pharmaceuticals Short Squeeze BioCryst Pharmaceuticals Short Squeeze Relay Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AUTL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings